BioGaia Granted New Patent in Europe
06-May-2005
The patent is based on several published clinical studies that show Reuteri's unique ability to significantly reduce problems that occur with severe diarrhoea.
"This new patent strengthens the protection of our products in the gut health area, in particular Reuteri Drops and Reuteri Tablets which are sold in Sweden and a series of other markets around the world," says Peter Rothschild MD BioGaia AB.
Most read news
Organizations
BioGaia
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.